822 results on '"William D Foulkes"'
Search Results
2. DICER1 screening in 15 paediatric paratesticular sarcomas unveils an unusual DICER1‐associated sarcoma
3. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
4. The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations
5. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
6. Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy
7. The effect of a DNA repair gene on cellular invasiveness: XRCC3 over-expression in breast cancer cells.
8. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
9. miRNA biogenesis and inherited disorders: clinico-molecular insights
10. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs
11. SMARCA4-associated schwannomatosis
12. Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss
13. Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention
14. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
15. Neuroectodermal elements are part of the morphological spectrum of DICER1-associated neoplasms
16. Supplementary Figure 1 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
17. Table S3 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
18. Data from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
19. Figure S4 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
20. Supplementary Table 1 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
21. Supplementary Methods from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
22. Supplementary Figure 2 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
23. Supplementary Figure 3 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
24. Tables S1, S2, S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
25. Supplementary Figure Legends and Materials and Methods from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
26. Data from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition
27. Supplemental Figures 1 - 10 from eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
28. Figure S1 from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
29. Supplementary Table 2 from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma
30. Supplementary Figure 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
31. Supplementary Figure 3 from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
32. Supplementary Figure 9 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
33. Data from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
34. Supplementary Figure 5 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
35. Supplementary Figure 7 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
36. Supplementary Tables and Figures from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma
37. Supplementary Figure 4 from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
38. Supplementary Figure 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
39. Supplementary Figure 3 from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
40. Data from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
41. Supplementary Figure 6 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
42. Supplementary Figure 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
43. Supplementary Notes from Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
44. Table S4 from SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
45. Supplementary Table 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
46. Supplementary Table 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
47. Supplementary Figure 2 from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
48. Supplementary Table 1 from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
49. Supplementary Table 3 from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma
50. Supplementary Figure 8 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.